Walleye Trading LLC Invests $131,000 in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Walleye Trading LLC acquired a new position in Theravance Biopharma, Inc. (NASDAQ:TBPHGet Rating) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 14,475 shares of the biopharmaceutical company’s stock, valued at approximately $131,000.

A number of other hedge funds have also recently made changes to their positions in the business. Woodline Partners LP increased its stake in shares of Theravance Biopharma by 130.7% in the first quarter. Woodline Partners LP now owns 1,326,653 shares of the biopharmaceutical company’s stock worth $12,683,000 after buying an additional 751,540 shares during the period. Vanguard Group Inc. increased its stake in shares of Theravance Biopharma by 10.3% in the first quarter. Vanguard Group Inc. now owns 6,947,947 shares of the biopharmaceutical company’s stock worth $66,421,000 after buying an additional 648,124 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Theravance Biopharma by 184.0% in the first quarter. Goldman Sachs Group Inc. now owns 976,373 shares of the biopharmaceutical company’s stock worth $9,335,000 after buying an additional 632,582 shares during the period. State Street Corp increased its stake in shares of Theravance Biopharma by 13.3% in the first quarter. State Street Corp now owns 1,541,533 shares of the biopharmaceutical company’s stock worth $14,737,000 after buying an additional 181,331 shares during the period. Finally, First Pacific Advisors LP purchased a new position in shares of Theravance Biopharma in the first quarter worth $1,336,000.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. SVB Leerink lifted their target price on shares of Theravance Biopharma from $12.00 to $14.00 and gave the stock an “outperform” rating in a research note on Thursday. StockNews.com raised shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a research report on Friday, November 11th. Finally, HC Wainwright boosted their price objective on shares of Theravance Biopharma from $12.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday, November 8th.

Theravance Biopharma Trading Down 4.3 %

Shares of Theravance Biopharma stock opened at $10.85 on Friday. The company’s fifty day simple moving average is $10.14 and its two-hundred day simple moving average is $9.47. The company has a market cap of $730.96 million, a P/E ratio of 0.96 and a beta of 0.52. Theravance Biopharma, Inc. has a 12-month low of $7.53 and a 12-month high of $13.17.

Theravance Biopharma Profile

(Get Rating)

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

See Also

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPHGet Rating).

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.